Evolus, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for EOLS, updated each market day.
EOLS AI Sentiment
AI predicts Evolus, Inc. Common Stock stock is likely to decrease over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Evolus, Inc. Common Stock
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.
Sector
Exchange
Market Cap
$275,854,357
Cap Tier
Employees
334
Headquarters
NEWPORT BEACH, CA
Listed Since
Feb. 8, 2018
Website
EOLS Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
EOLS Volatility
Evolus, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
